---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-24-000031"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:27:42.705760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter

## Summary
- Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%
- GAAP net earnings from continuing ops $5.35B ($2.20 diluted EPS) vs $0.49B loss in prior year (large litigation charges skewed comparison)
- Adjusted net earnings $6.58B, up 3.8%; adjusted diluted EPS $2.71 vs $2.41, +12.4%
- Board raises quarterly dividend to $1.24/share (from $1.19), a 4.2% increase; marks 62nd consecutive annual increase
- New indicated annual dividend $4.96/share; payable June 4, 2024 to holders of record May 21, 2024

## SEC filing metadata
- accession: 0000200406-24-000031
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/0000200406-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/jnj-20240416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-24-000031
- JSON: https://secwatch.observer/filing/0000200406-24-000031.json
- Plain text: https://secwatch.observer/filing/0000200406-24-000031.txt

## Key facts
- Earnings Releases
  JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383 million, net income $5,354 million, EPS $2.20.
  - Period: first quarter ended March 31, 2024
  - Revenue: $21,383 million
  - Net income: $5,354 million
  - EPS: $2.20
  - Result: reported results
  source text: On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/0000200406-24-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.